Navigation Links
Human Pheromone Sciences Announces Third Quarter Results
Date:11/13/2008

Increase in revenue with reduction in loss for the quarter

SAN JOSE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") today announced results for the third quarter and nine months ended September 30, 2008. For the three month period ending September 30, 2008, net revenues of $262,000 represented a 10% increase from the revenues of $239,000 in the prior year period, and resulted in a net loss of $30,000 ($.01 per share) as compared with a net loss of $93,000 ($.02 per share) for the same period of 2007. For the nine month period ending September 30, 2008, net revenues of $764,000 were 15% lower than the previous year's $902,000, resulting in a net loss of $181,000 ($0.04 per share) as compared with a net loss of $54,000 ($0.01 per share) in the first nine months of 2007. At September 30, 2008, the Company reflected a cash balance of $1,082,000 compared with $1,437,000 at December 31, 2007, a $355,000 reduction for the nine months of the current year as compared to a decline of $390,000 during the nine months ending September 30, 2007. There was no bank indebtedness at either date.

A spokesperson indicated "the Company was pleased that its cash utilization was only $355,000 for the first nine months of the year, and that net current liquidity (cash, accounts receivable and inventory, less current liabilities excluding current portion of deferred revenue) decreased only $433,000 for the same nine month period. This lower than expected asset utilization was a result of revenues generated under new licensing agreements, and a concerted effort to only invest in programs that are designed to generate additional future revenues."

"However, we still recognize that the marketing plans of our licensees can create unpredicted volatility of our quarterly performance, and this is not an acceptable posture for the Company in the long-term. We will still continue to nurture and expand our relationships with our licensees, and explore strategic ventures with other world-class marketing partners; we are also expanding our focus to include additional distribution channels for our current technology, as well as partners for the additional technologies we have developed."

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at http://www.erox.com.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-KSB for the year ended December 31, 2007, and Form 10-Q for the quarter ended September 30, 2008, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

Tables follow

HUMAN PHEROMONE SCIENCES, INC.

Condensed Balance Sheets

(Dollars in thousands)

September 30, December 31,

2008 2007

(Unaudited)

Assets

Cash and cash equivalents $ 1,082 $ 1,437

Accounts receivable 91 194

Inventories 50 25

Other current assets 34 40

Property and equipment, net 2 3

Total $1,259 $ 1,699

Liabilities and shareholders' equity

Accounts payable $31 $28

Other current liabilities 138 141

Deferred income - current 384 518

Deferred income - non-current 375 566

Common stock 21,029 20,963

Accumulated deficit (20,698) (20,517)

Total $1,259 $1,699

HUMAN PHEROMONE SCIENCES, INC.

Condensed Statements of Operations

(Unaudited)

(Dollars in thousands, except per-share data)

Three months Nine months

ended ended

September 30, September 30,

2008 2007 2008 2007

Net revenue $262 $239 $764 $902

Cost of goods sold 86 94 240 277

Research and development 10 10 33 38

Selling, general and administrative 203 240 696 686

Income (loss) from operations (37) (105) (205) (99)

Other income 7 16 25 50

Provision for income taxes - 4 1 5

Net income (loss) $(30) $(93) $(181) $(54)

Income (loss) per share -

Basic and fully diluted $(0.01) $(0.02) $(0.04) $(0.01)

Weighted average common shares

outstanding -

Basic and fully diluted 4,152 4,152 4,152 4,152

Net income (loss) per share is based on the weighted average number of common shares and common equivalents outstanding during each period. Certain common stock equivalents are excluded when their effect would be anti-dilutive.


'/>"/>
SOURCE Human Pheromone Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans
2. Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
3. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
4. Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments
5. Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
6. Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
7. Complete Genomics Chooses Isilon IQ to Power Worlds First Complete Human Genome Sequencing Service
8. Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results
9. Human Pheromone Sciences, Inc. - Shareholder Update
10. The human brain minimizes energy expenditure and integrates gravity in to the action plan
11. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Clinovo ... free and validated Electronic Data Capture (EDC) system ClinCaptureand its new Contract Research ... West Coast 2016 Conference in San Mateo, California on February 10th and 11th. ...
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove ... Policy for the National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove ... voices are heard throughout the drug regulatory review process. , “Adding Diane Dorman ...
(Date:2/9/2016)... , February 9, 2016 Three-Year ... Enables Children to Take Part in Life-Changing Camp ... new initiative designed to positively affect the lives of children born ... care. --> SHPG ) is announcing a new initiative ... diseases, as well as the future of rare disease care. ...
(Date:2/8/2016)... 2016 Should antibiotic bone cement products be ... prevent infection after standard total hip or knee replacement ... Institute have been fielding a lot lately. ... Line?" --> "Antibiotic Bone Cement: ... --> While there isn,t a simple answer, ...
Breaking Biology Technology:
(Date:1/22/2016)... Jan. 22, 2016 ... of the "Global Biometrics Market in ... offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ...
(Date:1/20/2016)... LONDON , Jan. 20, 2016 A ... positioned to directly benefit from the explosion in genomics ... from Howe Sound Research. A range of dynamic trends ... ...... - personalized medicine - pharmacogenomics - pathogen ... economies with large markets - greater understanding of the ...
(Date:1/20/2016)... JOSE, Calif. , Jan. 20, 2016 /PRNewswire/ ... developer of human interface solutions, today announced sampling ... controller solution for wearables and small screen applications ... such as printers. Supporting round and rectangular shapes, ... S1423 offers excellent performance with moisture on screen, ...
Breaking Biology News(10 mins):